MedPage Today on MSN
First twice-yearly biologic approved for severe eosinophilic asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
In the 12 months after starting tezepelumab, patients with severe asthma had fewer exacerbations, a lower cumulative oral ...
The Well News on MSN
FDA approves add-on treatment for severe asthma
WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...
FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
Asthma isn’t always a quick and easy diagnosis in children. According to a 2014 task force assembled by the American Thoracic Society and the European Respiratory Society, pediatric severe asthma can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results